Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T74937
(Former ID: TTDI02054)
|
|||||
Target Name |
Dopamine beta hydroxylase (DBH)
|
|||||
Synonyms |
Soluble dopamine betahydroxylase; Dopamine betamonooxygenase; Dopamine betahydroxylase; Dopamine beta-monooxygenase; Dopamine beta-hydroxylase
|
|||||
Gene Name |
DBH
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Heart failure [ICD-11: BD10-BD1Z] | |||||
2 | Post-traumatic stress disorder [ICD-11: 6B40] | |||||
Function |
Conversion of dopamine to noradrenaline.
Click to Show/Hide
|
|||||
BioChemical Class |
Paired donor oxygen oxidoreductase
|
|||||
UniProt ID | ||||||
EC Number |
EC 1.14.17.1
|
|||||
Sequence |
MPALSRWASLPGPSMREAAFMYSTAVAIFLVILVAALQGSAPRESPLPYHIPLDPEGSLE
LSWNVSYTQEAIHFQLLVRRLKAGVLFGMSDRGELENADLVVLWTDGDTAYFADAWSDQK GQIHLDPQQDYQLLQVQRTPEGLTLLFKRPFGTCDPKDYLIEDGTVHLVYGILEEPFRSL EAINGSGLQMGLQRVQLLKPNIPEPELPSDACTMEVQAPNIQIPSQETTYWCYIKELPKG FSRHHIIKYEPIVTKGNEALVHHMEVFQCAPEMDSVPHFSGPCDSKMKPDRLNYCRHVLA AWALGAKAFYYPEEAGLAFGGPGSSRYLRLEVHYHNPLVIEGRNDSSGIRLYYTAKLRRF NAGIMELGLVYTPVMAIPPRETAFILTGYCTDKCTQLALPPSGIHIFASQLHTHLTGRKV VTVLVRDGREWEIVNQDNHYSPHFQEIRMLKKVVSVHPGDVLITSCTYNTEDRELATVGG FGILEEMCVNYVHYYPQTQLELCKSAVDAGFLQKYFHLINRFNNEDVCTCPQASVSQQFT SVPWNSFNRDVLKALYSFAPISMHCNKSSAVRFQGEWNLQPLPKVISTLEEPTPQCPTSQ GRSPAGPTVVSIGGGKG Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
ADReCS ID | BADD_A06477 | |||||
HIT2.0 ID | T69T7P |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | Etamicastat | Drug Info | Phase 2 | Heart failure | [2] | |
2 | Nepicastat oral | Drug Info | Phase 2 | Post-traumatic stress disorder | [3], [4] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 2 Inhibitor drugs | + | ||||
1 | Etamicastat | Drug Info | [1] | |||
2 | Nepicastat oral | Drug Info | [5] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating Transcription Factors | ||||||
Target-interacting Proteins |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
BioCyc | [+] 1 BioCyc Pathways | + | ||||
1 | Catecholamine biosynthesis | |||||
KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
1 | Tyrosine metabolism | |||||
2 | Metabolic pathways | |||||
Panther Pathway | [+] 2 Panther Pathways | + | ||||
1 | Adrenaline and noradrenaline biosynthesis | |||||
2 | Dopamine receptor mediated signaling pathway | |||||
Pathwhiz Pathway | [+] 2 Pathwhiz Pathways | + | ||||
1 | Catecholamine Biosynthesis | |||||
2 | Tyrosine Metabolism | |||||
WikiPathways | [+] 3 WikiPathways | + | ||||
1 | Monoamine Transport | |||||
2 | Biogenic Amine Synthesis | |||||
3 | Metabolism of amino acids and derivatives |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42. | |||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034724) | |||||
REF 3 | ClinicalTrials.gov (NCT00641511) Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD). U.S. National Institutes of Health. | |||||
REF 4 | ClinicalTrials.gov (NCT01704196) A Multi-Center Trial of Nepicastat for Cocaine Dependence. U.S. National Institutes of Health. | |||||
REF 5 | Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.